In light of the limited success of CAR-T cell therapies for solid tumors, recent research has turned to CAR-NK cells as a potential alternative and has explored their efficacy against various solid tumor antigens, including HER-2 (235) and CD73 (236) in lung cancer, EGFRvIII in glioblastoma (237), EGFR in triple-negative breast cancer (238), mesothelin in gastric cancer (239), c−MET in liver cancer (240), PSMA in prostate cancer (241), EpCAM in colorectal cancer (242), and GPC3 in HCC (33). Here, EGFR is linked to triple-negative breast carcinoma.